Migraine affects more than 1 billion people worldwide. For many people, treatment options have long meant medications that come with side effects, risks, and uncertainty.
In 2004, CEFALY was founded with a clear mission: to give people with migraine a safe, drug-free option for relief and prevention.
More than two decades of clinical research, engineering innovation, and patient feedback have helped make CEFALY a leading neuromodulation device for migraine. Our work continues to focus on expanding what’s possible through science and technology.
Accessible to All
Evidence-Based
Patient-First
CEFALY Marks a Milestone: #1 Neuromodulation Device Prescribed by Veterans Health Administration Providers
Medical device maker CEFALY Technology announced today that CEFALY Connected has become the most frequently used neuromodulation device for migraine among veterans served by the Veterans Health Administration.
International Headache Society Evidence-Based Guidelines on the Use of Non-Invasive Neuromodulation Devices for the Acute and Preventive Treatment of Migraine
In adult subjects with EM with and without aura, Cefaly is superior to active sham for the treatment of acute migraine attacks.
Digital Migraine Treatment Devices Market to Reach USD 298.71 Million by 2030, Fueled by Non-Invasive Neuromodulation and Expanding Clinical Adoption
[CEFALY’s] proven efficacy in reducing episodic migraine frequency has made them the first-line device option in both the U.S. and European markets.
We’re not big pharma. We’re an accelerating technology company based in Belgium and the U.S. Many of us on the CEFALY team live with migraine ourselves. We support migraine research and advocate for the rights of people with migraine worldwide.
